CTTQ-Akeso
CTTQ-Akeso (Shanghai) Biomed. Tech. Co., Ltd. (CTTQ-Akeso), with registered capital of RMB 690 million, is an innovative biomedical company jointly established by Akeso, Inc. (9926.HK) and Chia Tai Tianqing Pharmaceutical Group Co., Ltd... CTTQ-Akeso focuses on the R&D of innovative biologics, industrialization of research results, technology transfer and commission processing, and is committed to the R&D and commercialization of the anti PD-1 monoclonal antibody drug Penpulimab monoclonal antibody injection (安尼可®) for tumor immunotherapy.
In April 2023，CTTQ-Akesoentered into a partnership agreement with Specialised Therapeutics （ST）to commercialise 安尼可® in Australia, New Zealand, Papua New Guinea and 11 countries in Southeast Asia including Singapore and Malaysia.The total consideration for the cooperation amounts to approximately US$73 million, and CTTQ-Akeso shall be entitled to a double-digit commission on the net sales of the drug in authorized regions.Through differentiated advantages of 安尼可® ，the partnership will robust its market presence in Southeast Asia and has become a powerful extension and supplement of the company's commercialization system in overseas markets.
安尼可® (Penpulimab injection)
At present, 安尼可® is the only PD-1 monoclonal antibody that applies the immunoglobulin G1 (‘‘IgG1’’) subtype modified by the fragment crystallizable (Fc) segment in the world, which has a lower antigen binding off-rate and a unique binding epitope as demonstrated by analysis on crystal structure. These features allow 安尼可® to effectively and continuously block PD-1/PD-L1 binding, thus differentiating it from PD-1 products on the market, and may enable安尼可® to more effectively enhance immunotherapeutic efficacy and reduce immune-related adverse reactions. The main indications for安尼可® include lung cancer, liver cancer, gastric cancer, nasopharyngeal cancer, esophageal cancer, classical Hodgkin’s lymphoma, mesothelioma, thymic cancer, urothelial cancer, bile duct cancer and neuroendocrine cancer. Currently,安尼可® has been approved by the National Medical Products Administration of China (NMPA) for ：first-line treatment of recurrent or metastatic nasopharyngeal cancer (NPC) in combination with chemotherapy; first-line treatment of locally advanced or metastatic squamous NSCLC; treatment of relapsed or refractory classical Hodgkin's lymphoma (r/r cHL) after at least second-line systemic therapy; and third-line treatment of metastatic nasopharyngeal cancer chemotherapy. 安尼可® (penpulimab-kcqx) has also been granted marketing approval by the FDA in two BLA indications for comprehensive treatment of advanced nasopharyngeal carcinoma (NPC) ：first-line treatment of adult recurrent or metastatic non-keratinizing NPC in combination with cisplatin or carboplatin and gemcitabine;monotherapy for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and with at least one other prior line of therapy.
Fenglin Building, No.420 Fenglin Road, Xuhui District, Shanghai
400-008-5183 (working days: 9:00–17:00)
Note: If your report involves an adverse event of CTTQ-Akeso’s products, the relevant patient information and data will be disclosed to CTTQ-Akeso’s pharmacovigilance department in accordance with the applicable laws and regulations, and the relevant personnel may follow up with you on the adverse event. The information will be input into CTTQ-Akeso’s drug safety database and may be legally required to reported to relevant regulatory departments.